



Radiant Bio Closes \$35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ Platform

Funding co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures to advance a new class of multi-functional biologics

TORONTO, Canada and PHILADELPHIA -- Sept. 11, 2024 (BusinessWire) – [Radiant Biotherapeutics](#), a preclinical biotechnology company developing an antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has closed a \$35 million Series A financing. The round is co-led by the [Bill & Melinda Gates Foundation](#) and [Amplitude Ventures](#) of Canada.

Additional participants in the Series A include new investors [BDC Capital](#), the investment arm of the Business Development Bank of Canada, through its Thrive Venture Fund, and abrdn plc of Edinburgh, Scotland; and existing investors [FACIT](#), [Alexandria Venture Investments](#) and [Toronto Innovation Acceleration Partners](#) (TIAP).

Radiant has built a best-in-class, proprietary, multi-valent, multi-specific antibody platform called Multabody™. The funds will enable Radiant to further develop the company's lead clinical candidate, 4-1BB, and move it towards clinical trials.

“These supportive investors share our vision of delivering powerful, multi-functional biologics with the potential to advance treatments for patients suffering from debilitating and life-threatening illnesses,” said Arthur J. Fratamico, President and CEO of Radiant. “This investment enables us to further demonstrate the unique power and breadth of our platform across multiple therapeutic areas with a focus in oncology, inflammation and immunology, and global health and infectious disease including HIV.”



Multabody™ therapeutics are able to overcome the shortcomings of existing antibody approaches by leveraging remarkable avidity, or binding strength, on their intended targets. Multabodies also exploit multi-specificity, enabling targeting of different disease-modifying proteins as well as multiple epitopes on the same target. Together, these qualities give Multabody™ therapeutics exceptional potency against both solid tumors and blood cancers, infectious disease pathogens, and other targets in multiple therapeutic areas.

“This financing will enable the next stage in Radiant’s growth and move the company towards the clinic as it continues to demonstrate the superiority of the Multabody™ platform against therapeutic targets that cannot be treated with traditional antibodies,” said Bharat Srinivasa, Ph.D., principal at Amplitude Ventures. “We are investing to accelerate Radiant’s transition to clinical stage and to expand its pipeline in additional therapeutic areas.”

Radiant Biotherapeutics was founded in 2020 and is built around foundational science developed at The [Hospital for Sick Children](#) (SickKids) in Toronto and the [University of Toronto](#), based on and including work performed at the laboratories of Jean-Philippe Julien, Ph.D., senior scientist at SickKids and associate professor at University of Toronto’s [Temerty Faculty of Medicine](#), and Bebhinn Treanor, Ph.D., a professor at the University of Toronto. The company emerged from stealth mode in 2023 following a seed investment led by Amplitude Ventures, FACIT, TIAP and Alexandria Venture Investments. Radiant maintains offices in Toronto and Philadelphia.

###

About Radiant Biotherapeutics

Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients.

Radiant’s proprietary Multabody™ platform leverages avidity and multi-specificity simultaneously, to generate highly efficacious Multabodies with superior potency than other

antibody platforms. These powerful Multabodies are a new class of biologics positioned to tackle complex, heterogenous diseases such as cancer, that often have challenging targets and mechanisms. Multabody™ production and manufacturing is flexible, modular and scalable, and



leverages standard antibody CMC processes. The groundbreaking efficiency of the platform is driving a novel pipeline of mono-, bi- and tri-specific biologics in multiple therapeutics areas. With offices in Toronto and Philadelphia, Radiant has forged multiple strategic partnerships that validate the Multabody™ platform's broad scientific and clinical utility. For more, visit radiantbio.com.

About Amplitude Ventures

Amplitude Ventures is a full-stack venture capital firm using a unique growth model to build companies with world-class management teams and to scale companies to breakout potential. With more than \$500 million in assets under management and offices in Montreal, Toronto, and Vancouver, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies. Visit <http://amplitudevc.com> to learn more.

Radiant Biotherapeutics Media Contact:

Jeffrey Krasner

[Slowey McManus Communications](http://SloweyMcManusCommunications)

jkrasner@sloweymcmanus.com

+1-617-840-9806